Quantitative determination of oncostatin M in IBD patients
The IDK Oncostatin M (OSM) ELISA is used for the quantitative determination of oncostatin M in serum, plasma or stools. OSM and its receptor, OSMR, are involved in gut inflammation, and are upregulated in the mucosa of IBD patients. The amount of OSM in the gut mucosa can be a predictive biomarker of no response (primary non-response), and loss or response, to anti-TNFα treatment in IBD patients, and could be useful as a diagnostic tool for early stratification of patients to predict the efficacy of treatment.